Drug intelligence / Profile preview

EB9092

Development stage: Preclinical
Lead developer: Empath Biosciences
Modality: Small Molecules

Overview

EB9092 is a small molecule glycomacrolide being developed by EmpathBio for the treatment of leukemia and solid tumors. It specifically targets the F subunit of the ATP synthase/hydrolase complex, an essential component of the mitochondrial electron transport chain responsible for ATP synthesis. By inhibiting this subunit, EB9092 disrupts the energy metabolism of cancer cells, which often exhibit increased reliance on mitochondrial function for survival and resistance to therapy. The drug is currently in the IND-enabling stage of development.

Targets

F1-ATPase (ATP synthase F1 sector)ATP5MF (ATP synthase peripheral stalk-membrane subunit f)

Beyond the preview

Go deeper on EB9092.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB9092.